Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2023 Filed Jun 20, 2023 17:53 UTC |
Pridgen WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-23-009983 · form4-06202023_050635.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option will vest 100% on June 14, 2024, one year following the grant date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 23:33 UTC |
Duncan Gregory ScottDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (right to buy) · Derivative | 480,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-22-012561 · form4-12142022_111237.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 23:32 UTC |
Walsh AngelaSVP OF FINANCE
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-22-012560 · form4-12142022_111252.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 23:31 UTC |
Grosswald RalphSVP OF OPERATIONS
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-22-012559 · form4-12142022_111254.xml · derivative · entry 1 Grosswald Ralph · CIK 0001826084 · SVP OF OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 23:30 UTC |
Gendreau Roger MichaelCHIEF MEDICAL OFFICER
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-22-012558 · form4-12142022_111202.xml · derivative · entry 1 Gendreau Roger Michael · CIK 0001826131 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. Read SEC document |
| December 12, 2022 Filed Feb 15, 2023 17:54 UTC Amendment |
Duncan Gregory ScottDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001415889-23-002583 · form4a-02152023_050206.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2032-12-12 F1 · shares: The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options. F2 · derivative.exercise_date: The stock option vests one-third on December 12, 2023 and 1/24th monthly thereafter. F1 · derivative.underlying_shares: The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options. F1 · balance_after: The reporting person filed a Form 4 on December 14, 2022 which incorrectly reported that on December 12, 2022 he was granted 480,000 Stock Options. This Form 4 amendment is being filed for the purpose of amending and restating the Form 4 to reflect that the reporting person was granted 410,000 Stock Options. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 18:39 UTC |
Whitley Richard JamesDirector
|
SaleCommon Stock | 1,800 | $0.26 | $466.38 |
DisclosureSEC source: 0001415889-22-012370 · form4-12122022_061240.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:09 UTC |
Whitley Richard JamesDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007096 · form4-06302022_110649.xml · derivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:08 UTC |
Pridgen WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007094 · form4-06302022_110603.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:05 UTC |
Burch Richard AlanDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007092 · form4-06302022_110636.xml · derivative · entry 1 Burch Richard Alan · CIK 0001837084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:03 UTC |
Keefer David RDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007089 · form4-06302022_110615.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:01 UTC |
Thomas John CDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007087 · form4-06302022_110637.xml · derivative · entry 1 Thomas John C · CIK 0001424620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:59 UTC |
De La Rosa AbelDirector
|
GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007085 · form4-06302022_100643.xml · derivative · entry 1 De La Rosa Abel · CIK 0001825983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:53 UTC |
Gendreau Roger MichaelCHIEF MEDICAL OFFICER
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007083 · form4-06302022_100635.xml · derivative · entry 1 Gendreau Roger Michael · CIK 0001826131 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:43 UTC |
Grosswald RalphSVP OF OPERATIONS
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007080 · form4-06302022_100659.xml · derivative · entry 1 Grosswald Ralph · CIK 0001826084 · SVP OF OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:38 UTC |
Duncan Gregory ScottDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007076 · form4-06302022_100647.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 17:40 UTC |
Walsh AngelaSVP OF FINANCE
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007078 · form4-06302022_100642.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option vests one-third on June 23, 2023 and 1/24th monthly thereafter. Read SEC document |
| May 23, 2022 Filed May 24, 2022 18:53 UTC |
Walsh AngelaSVP OF FINANCE
|
PurchaseCommon Stock | 2,000 | $4.58 | $9,150.00 |
DisclosureSEC source: 0001415889-22-005575 · form4-05242022_110533.xml · nonDerivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 3,000 Read SEC document |
| May 23, 2022 Filed May 24, 2022 14:24 UTC |
Duncan Gregory ScottDirector · CHIEF EXECUTIVE OFFICER
|
PurchaseCommon Stock | 7,500 | $4.52 | $33,900.00 |
DisclosureSEC source: 0001415889-22-005567 · form4-05242022_070548.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,461 Read SEC document |
| May 18, 2022 Filed May 19, 2022 15:48 UTC |
Whitley Richard JamesDirector
|
PurchaseCommon Stock | 500 | $4.53 | $2,262.50 |
DisclosureSEC source: 0001415889-22-005275 · form4-05192022_080533.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| May 18, 2022 Filed May 19, 2022 15:44 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 241 | $4.50 | $1,084.50 |
DisclosureSEC source: 0001415889-22-005272 · form4-05192022_080545.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 36,710 F1 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| May 17, 2022 Filed May 18, 2022 15:24 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 13,450 | $4.38 | $58,913.69 |
DisclosureSEC source: 0001415889-22-005214 · form4-05182022_080517.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 36,469 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.94 to $4.57, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 15:55 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 600 | $4.94 | $2,964.48 |
DisclosureSEC source: 0001415889-22-003465 · form4-03302022_080315.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 23,019 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.94 to $4.97, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 18:52 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 2,197 | $5.46 | $12,001.55 |
DisclosureSEC source: 0001415889-22-003314 · form4-03242022_110324.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 22,419 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.37 to $5.48, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Reflects corrected holdings, as prior reports incorrectly understated indirect holdings and overstated direct holdings, by 1,500 shares. F3 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 20:30 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 4,180 | $5.98 | $24,997.65 |
DisclosureSEC source: 0001415889-22-000846 · form4-01282022_120112.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 18,722 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.80 to $6.27, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 22:24 UTC |
De La Rosa AbelDirector
|
PurchaseCommon Stock | 4,000 | $5.90 | $23,584.00 |
DisclosureSEC source: 0001415889-22-000462 · form4-01072022_020119.xml · nonDerivative · entry 1 De La Rosa Abel · CIK 0001825983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.8375 to $6.00, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 18:14 UTC |
Whitley Richard JamesDirector
|
PurchaseCommon Stock | 1,800 | $5.72 | $10,296.00 |
DisclosureSEC source: 0001415889-22-000447 · form4-01072022_100133.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 20:19 UTC |
Thomas John CDirector
|
PurchaseCommon Stock | 1,000 | $5.65 | $5,650.00 |
DisclosureSEC source: 0001415889-22-000165 · form4-01042022_120143.xml · nonDerivative · entry 1 Thomas John C · CIK 0001424620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 20:12 UTC |
Keefer David RDirector
|
PurchaseCommon Stock | 5,000 | $5.80 | $28,975.00 |
DisclosureSEC source: 0001415889-22-000350 · form4-01052022_120151.xml · nonDerivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.75 to $5.80, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 20:23 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 2,215 | $5.43 | $12,033.87 |
DisclosureSEC source: 0001415889-22-000167 · form4-01042022_120157.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 14,542 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.20 to $5.70, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| December 23, 2021 Filed Dec 23, 2021 20:59 UTC |
Whitley Richard JamesDirector
|
PurchaseCommon Stock | 200 | $5.73 | $1,145.00 |
DisclosureSEC source: 0001415889-21-006204 · form4-12232021_121238.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 18:28 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 8,827 | $5.66 | $49,997.01 |
DisclosureSEC source: 0001415889-21-006174 · form4-12222021_101232.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401 (k) Account Disclosed balance after: 12,327 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.375 to $5.8799, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 18:23 UTC |
Duncan Gregory ScottDirector · CHIEF EXECUTIVE OFFICER
|
PurchaseCommon Stock | 5,000 | $5.52 | $27,615.00 |
DisclosureSEC source: 0001415889-21-006172 · form4-12222021_101249.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,961 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.395 to $5.708, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 17:36 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 942 | $6.32 | $5,950.61 |
DisclosureSEC source: 0001415889-21-003569 · form4-07092021_100738.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,734 F1 · shares: This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · balance_after: Does not include 18,201 shares that were previously reported on the reporting person's Form 3 and prior Forms 4. Such shares were included in the person's holdings in error. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:59 UTC |
Burch Richard AlanDirector
|
GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003156 · form4-06232021_110634.xml · derivative · entry 1 Burch Richard Alan · CIK 0001837084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 19:26 UTC |
Pridgen WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003158 · form4-06232021_120654.xml · derivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:55 UTC |
Whitley Richard JamesDirector
|
GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003154 · form4-06232021_110634.xml · derivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:52 UTC |
Thomas John CDirector
|
GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003152 · form4-06232021_110629.xml · derivative · entry 1 Thomas John C · CIK 0001424620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:48 UTC |
Keefer David RDirector
|
GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003150 · form4-06232021_110655.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:42 UTC |
De La Rosa AbelDirector
|
GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003148 · form4-06232021_110653.xml · derivative · entry 1 De La Rosa Abel · CIK 0001825983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:05 UTC |
Walsh AngelaSVP OF FINANCE
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-21-003146 · form4-06222021_020636.xml · derivative · entry 1 Walsh Angela · CIK 0001825987 · SVP OF FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:01 UTC |
Grosswald RalphVICE PRESIDENT OF OPERATIONS
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-21-003144 · form4-06222021_020609.xml · derivative · entry 1 Grosswald Ralph · CIK 0001826084 · VICE PRESIDENT OF OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 20:58 UTC |
Duncan Gregory ScottDirector · CHIEF EXECUTIVE OFFICER
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-21-003142 · form4-06222021_010611.xml · derivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: The stock option vests one-third on June 21, 2022 and 1/24th monthly thereafter. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 17:59 UTC |
Duncan Gregory ScottDirector · Chief Executive Officer
|
PurchaseCommon Stock | 382 | $6.36 | $2,428.60 |
DisclosureSEC source: 0001104659-21-047486 · tm2112418-1_4seq1.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,961 F1 · shares: This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 01:56 UTC Amendment |
Duncan Gregory ScottDirector · Chief Executive Officer
|
PurchaseCommon Stock | 15,675 | $6.17 | $96,757.07 |
DisclosureSEC source: 0001104659-21-047253 · tm2112349d1_4a.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,579 F1 · shares: This purchase was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 19:38 UTC |
Duncan Gregory ScottDirector · Chief Executive Officer
|
PurchaseCommon Stock | 15,675 | $6.17 | $96,757.07 |
DisclosureSEC source: 0001104659-21-047069 · tm2112297-1_4.xml · nonDerivative · entry 1 Duncan Gregory Scott · CIK 0001831127 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,579 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 00:54 UTC |
Pridgen WilliamDirector
|
PurchaseCommon Stock | 3,500 | $7.47 | $26,145.00 |
DisclosureSEC source: 0001104659-21-010386 · tm214953-2_4seq1.xml · nonDerivative · entry 2 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Account Disclosed balance after: 3,500 F1 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC |
Walsh AngelaVP of Finance
|
PurchaseCommon Stock | 1,000 | $7.30 | $7,300.00 |
DisclosureSEC source: 0001104659-21-010387 · tm214953-3_4seq1.xml · nonDerivative · entry 1 Walsh Angela · CIK 0001825987 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 1,000 Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC |
Pridgen WilliamDirector
|
Exercise / conversionWarrant to Purchase Common Stock · Derivative | 801 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-21-010386 · tm214953-2_4seq1.xml · derivative · entry 3 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 801 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: The Reporting Person provided notice of exercise to the Issuer on January 20, 2021 and the Company authorized the issuance of the shares pursuant to such exercise on January 28, 2020. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC |
Pridgen WilliamDirector
|
Exercise / conversionCommon Stock | 801 | $7.80 | $6,247.80 |
DisclosureSEC source: 0001104659-21-010386 · tm214953-2_4seq1.xml · nonDerivative · entry 1 Pridgen William · CIK 0001826115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.